Drug Induced Liver Injury Clinical Trial
Official title:
Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury: A Prospective Randomized Controlled Trial
Intervention - Subjects will be randomized to 2 groups
Group A - subjects will receive Prednisolone for 20 days with NAC (N-Acetylcysteine)
Group B - will receive NAC (N-Acetylcysteine) only NAC (N-acetylcysteine) dosing
Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1
hour
Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h
Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
- Monitoring and assessment-Liver Biopsy at baseline and at 3 months, Liver Function Test
at regular intervals.
- Stopping rule-Development of sepsis, worsening of Liver functions.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
| Completed |
NCT01000766 -
Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury
|
N/A | |
| Recruiting |
NCT00360646 -
Drug-Induced Liver Injury (DILI) Network Retrospective
|
||
| Recruiting |
NCT05789797 -
Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
|
||
| Active, not recruiting |
NCT04269486 -
A Multicenter Observational Study on Safety of the Herbal Medicines at Inpatient Setting
|
||
| Recruiting |
NCT06192589 -
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
|
Phase 1 | |
| Completed |
NCT00616018 -
Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
|
Phase 4 | |
| Withdrawn |
NCT01137591 -
Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever
|
N/A |